Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4862774
Max Phase: Preclinical
Molecular Formula: C22H16FNO2
Molecular Weight: 345.37
Molecule Type: Unknown
Associated Items:
ID: ALA4862774
Max Phase: Preclinical
Molecular Formula: C22H16FNO2
Molecular Weight: 345.37
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C1CCCC2=C1C(c1ccc(F)cc1)C1=C(N2)c2ccccc2C1=O
Standard InChI: InChI=1S/C22H16FNO2/c23-13-10-8-12(9-11-13)18-19-16(6-3-7-17(19)25)24-21-14-4-1-2-5-15(14)22(26)20(18)21/h1-2,4-5,8-11,18,24H,3,6-7H2
Standard InChI Key: KFLIOKJTSVBDDC-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 345.37 | Molecular Weight (Monoisotopic): 345.1165 | AlogP: 4.13 | #Rotatable Bonds: 1 |
Polar Surface Area: 46.17 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.05 | CX LogD: 3.05 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.85 | Np Likeness Score: -0.79 |
1. (2020) Inhibitors of GPR174 and Uses Thereof, |
2. (2020) Methods and Compositions for Treating Cancer, |
Source(1):